176 related articles for article (PubMed ID: 27342497)
21. Biological characterization of nodal versus extranodal presentation of diffuse large B-Cell lymphoma using immunohistochemistry.
Kim MK; Bae SH; Bae YK; Kum YS; Ryoo HM; Cho HS; Lee KH; Koh SA; Lee HY; Yun SY; Choi JH; Hyun MS
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):403-8. PubMed ID: 21700526
[TBL] [Abstract][Full Text] [Related]
22. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
[TBL] [Abstract][Full Text] [Related]
23. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
[TBL] [Abstract][Full Text] [Related]
24. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
25. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
26. The pretreatment albumin to globulin ratio as a significant predictor in patients with diffuse large B cell lymphoma.
Yue W; Liu B; Gao L; He M; Wang J; Zhang W; Chen L; Hu X; Xu L; Yang J
Clin Chim Acta; 2018 Oct; 485():316-322. PubMed ID: 30006285
[TBL] [Abstract][Full Text] [Related]
27. [Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma].
Liang X; Wang J; Bai W; Sun R
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):559-64. PubMed ID: 26705179
[TBL] [Abstract][Full Text] [Related]
28. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.
Hwang HS; Yoon DH; Suh C; Huh J
Ann Hematol; 2016 Aug; 95(8):1249-58. PubMed ID: 27167532
[TBL] [Abstract][Full Text] [Related]
29. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
[No Abstract] [Full Text] [Related]
30. Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis.
Rodrigues-Fernandes CI; Abreu LG; Radhakrishnan R; Perez DEDC; Amaral-Silva GK; Gondak RO; Rahimi S; Brennan PA; Fonseca FP; Vargas PA
J Oral Pathol Med; 2021 Jul; 50(6):587-593. PubMed ID: 34101913
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
Bartlett NL; Smith MR; Siddiqi T; Advani RH; O'Connor OA; Sharman JP; Feldman T; Savage KJ; Shustov AR; Diefenbach CS; Oki Y; Palanca-Wessels MC; Uttarwar M; Li M; Yang J; Jacobsen ED
Leuk Lymphoma; 2017 Jul; 58(7):1607-1616. PubMed ID: 27868471
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma.
Alacacioglu I; Ozcan MA; Ozkal S; Piskin O; Turgut N; Demirkan F; Ozsan GH; Kargi A; Undar B
Hematology; 2009 Apr; 14(2):84-9. PubMed ID: 19298719
[TBL] [Abstract][Full Text] [Related]
33. [CD5 expression is an adverse prognostic factor in diffuse large B-cell lymphoma].
Zheng Y; Ma XB; Jiang J; Wang YP
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):156-60. PubMed ID: 22800477
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
[TBL] [Abstract][Full Text] [Related]
35. [The clinical characteristics and prognostic analysis of 147 cases of diffuse large B-cell lymphoma].
Zhao Q; Fu WJ; Zhang CY; Du J; Xi H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):737-40. PubMed ID: 24103868
[TBL] [Abstract][Full Text] [Related]
36. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era.
Jing XM; Yu JR; Luo YK; Zhang SC; Liu JF; Li L; Wu P; Zhang ZH
Leuk Res; 2017 Sep; 60():89-93. PubMed ID: 28772206
[TBL] [Abstract][Full Text] [Related]
38. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
Antic D; Jelicic J; Trajkovic G; Balint MT; Bila J; Markovic O; Petkovic I; Nikolic V; Andjelic B; Djurasinovic V; Sretenovic A; Smiljanic M; Vukovic V; Mihaljevic B
Ann Hematol; 2018 Feb; 97(2):267-276. PubMed ID: 29130134
[TBL] [Abstract][Full Text] [Related]
39. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
40. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
